Intracerebral hemorrhage associated with oral anticoagulant therapy: Current practices and unresolved questions

Stroke

Volumn 37, Issue 1, 2006, Pages 256-262

  Steiner, Thorsten ^a   Rosand, Jonathan ^b   Diringer, Michael ^c  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Etiology; Intracerebral hemorrhage; Oral anticoagulant agents; Therapy; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR; COUMARIN; FRESH FROZEN PLASMA; PROTHROMBIN COMPLEX; RECOMBINANT ACTIVATED FACTOR VII; UNCLASSIFIED DRUG; VITAMIN K GROUP; BLOOD CLOTTING FACTOR 7A; RECOMBINANT PROTEIN;

ANTICOAGULATION; BLOOD CLOTTING DISORDER; BRAIN HEMORRHAGE; DRUG INDICATION; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; THROMBOSIS; BLEEDING; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; METABOLISM; ORAL DRUG ADMINISTRATION; RISK;

ADMINISTRATION, ORAL; ANTICOAGULANTS; CEREBRAL HEMORRHAGE; CLINICAL TRIALS; FACTOR VIIA; HEMORRHAGE; HUMANS; RECOMBINANT PROTEINS; RISK; THROMBOSIS; VITAMIN K;

EID: 33644878260     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000196989.09900.f8     Document Type: Review

References (81)

1. Brott T, Broderick J, Kothari R, Barsan W, Tomsick T, Sauerbeck L, Spilker J, Duldner J, Khoury J. Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke. 1997;28:1-5.
2. Juvela S. Risk factors for impaired outcome after spontaneous intracerebral hemorrhage. Arch Neurol. 1995;52:1193-1200.
3. Franke CL, de Jonge J, van Swieten JC, Op de Coul AA, van Gijn J. Intracerebral hematomas during anticoagulant treatment. Stroke. 1990;21:726-730.
4. Rosand J, Eckman MH, Knudsen KA, Singer DE, Greenberg SM. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med. 2004;164:880-884.
5. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154:1449-1457.
6. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285:2370-2375.
7. Weimar C, Weber C, Wagner M, Busse O, Haberl RL, Lauterbach KW, Diener HC. Management patterns and health care use after intracerebral hemorrhage. A cost-of-illness study from a societal perspective in Germany. Cerebrovasc Dis. 2003;15:29-36.
8. Broderick JP, Brott T, Tomsick T, Huster G, Miller R. The risk of subarachnoid and intracerebral hemorrhages in blacks as compared with whites. N Engl J Med. 1992;326:733-736.
9. Butler AC, Tait RC. Management of oral anticoagulant-induced intracranial haemorrhage. Blood Rev. 1998;12:35-44.
10. Hart RG, Boop BS, Anderson DC. Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses. Stroke. 1995;26:1471-1477.
11. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet. 1996;348:633-638.
12. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation. Stroke Prevention in Atrial Fibrillation II Study. Lancet. 1994;343:687-691.
13. Nilsson OG, Lindgren A, Stahl N, Brandt L, Saveland H. Incidence of intracerebral and subarachnoid haemorrhage in southern Sweden. J Neurol Neurosurg Psychiatry. 2000;69:601-607.
14. Sudlow CL, Warlow CP. Comparable studies of the incidence of stroke and its pathological types: results from an international collaboration. International Stroke Incidence Collaboration. Stroke. 1997;28:491-499.
15. Kolominsky-Rabas PL, Sarti C, Heuschmann PU, Graf C, Siemonsen S, Neundoerfer B, Katalinic A, Lang E, Gassmann KG, von Stockert TR. A prospective community-based study of stroke in Germany - the Erlangen Stroke Project (ESPro): incidence and case fatality at 1, 3, and 12 months. Stroke. 1998;29:2501-2506.
16. Deleted in proof.
17. Stroke Prevention in Atrial Fibrillation Investigators. Bleeding during antithrombotic therapy in patients with atrial fibrillation. Arch Intern Med. 1996;156:409-416.
18. Flibotte JJ, Hagan N, O'Donnell J, Greenberg SM, Rosand J. Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology. 2004;63:1059-1064.
19. Gage BF, Birman-Deych E, Kerzner R, Radford MJ, Nilasena DS, Rich MW. Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall. Am J Med. 2005;118:612-617.
20. Hart RG. What causes intracerebral hemorrhage during warfarin therapy? Neurology. 2000;55:907-908.
21. Roob G, Schmidt R, Kapeller P, Lechner A, Hartung HP, Fazekas F. MRI evidence of past cerebral microbleeds in a healthy elderly population. Neurology. 1999;52:991-994.
22. Rosand J, Hylek EM, O'Donnell HC, Greenberg SM. Warfarin-associated hemorrhage and cerebral amyloid angiopathy: a genetic and pathologic study. Neurology. 2000;55:947-951.
23. Yasaka M, Minematsu K, Yamaguchi T. Optimal intensity of international normalized ratio in warfarin therapy for secondary prevention of stroke in patients with non-valvular atrial fibrillation. Intern Med. 2001;40:1183-1188.
24. Gorter JW. Major bleeding during anticoagulation after cerebral ischemia: patterns and risk factors. Stroke Prevention In Reversible Ischemia Trial (SPIRIT). European Atrial Fibrillation Trial (EAFT) study groups. Neurology. 1999;53:1319-1327.
25. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Annals of Neurology. 1997;42:857-865.
26. Smith EE, Rosand J, Knudsen KA, Hylek EM, Greenberg SM. Leukoaraiosis is associated with warfarin-related hemorrhage following ischemic stroke. Neurology. 2002;59:193-197.
27. Hylek E, Singer DE. Risk factor for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med. 1994;120:897-902.
28. Perry DJ. Factor VII Deficiency. Br J Haematol. 2002;118:689-700.
29. Mariani G, Herrmann FH, Dolce A, Batorova A, Etro D, Peyvandi F, Wulff K, Schved JF, Auerswald G, Ingerslev J, Bernardi F. Clinical phenotypes and factor VII genotype in congenital factor VII deficiency. Thromb Haemost. 2005;93:481-487.
30. Mayer SA. Ultra-early hemostatic therapy for intracerebral hemorrhage. Stroke. 2003;34:224-229.
31. Kazui S, Naritomi H, Yamamoto H, Sawada T, Yamaguchi T. Enlargement of spontaneous intracerebral hemorrhage. Incidence and time course. Stroke. 1996;27:1783-1787.
32. Becker KJ, Baxter AB, Bybee HM, Tirschwell DL, Abouelsaad T, Cohen WA. Extravasation of radiographic contrast is an independent predictor of death in primary intracerebral hemorrhage. Stroke. 1999;30:2025-2032.
33. Yasaka M, Minematsu K, Naritomi H, Sakata T, Yamaguchi T. Predisposing factors for enlargement of intracerebral hemorrhage in patients treated with warfarin. Thromb Haemost. 2003;89:278-283.
34. Zazulia AR, Diringer MN, Videen TO, Adams RE, Yundt K, Aiyagari V, Grubb RL Jr, Powers WJ. Hypoperfusion without ischemia surrounding acute intracerebral hemorrhage. J Cereb Blood Flow Metab. 2001;21:804-810.
35. Schellinger PD, Fiebach JB, Hoffmann K, Becker K, Orakcioglu B, Kollmar R, Juttler E, Schramm P, Schwab S, Sartor K, Hacke W. Stroke MRI in intracerebral hemorrhage: is there a perihemorrhagic penumbra? Stroke. 2003;34:1674-1679.
36. Sansing LH, Kaznatcheeva EA, Perkins CJ, Komaroff E, Gutman FB, Newman GC. Edema after intracerebral hemorrhage: correlations with coagulation parameters and treatment. J Neurosurg. 2003;98:985-992.
37. Mayer S, Brun N, Broderick J, Davis S, Diringer M, Skolnick B, Steiner T; for the Europe/Australasia NovoSeven ICH Trial Investigators. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2005;352:777-785.
38. Boulis NM, Bobek MP, Schmaier A, Hoff JT. Use of factor IX complex in warfarin-related intracranial hemorrhage. Neurosurgery. 1999;45:1113-1118; discussion 1118-1119.
39. Freeman WD, Brott TG, Barrett KM, Castillo PR, Deen HG Jr, Czervionke LF, Meschia JF. Recombinant factor VIIa for rapid reversal of warfarin anticoagulation in acute intracranial hemorrhage. Mayo Clin Proc. 2004;79:1495-1500.
40. Fewel ME, Park P. The emerging role of recombinant-activated factor VII in neurocritical care. Neurocritical Care. 2004;1:19-30.
41. O'Reilly RA. Warfarin metabolism and drug-drug interaction. In: Wessler S, Becker CG, Y N, eds. Advances in experimental medicine and biology. New York: Plenum; 1986:205-212.
42. Beeck H, Hellstern P. In vitro characterization of solvent/detergent- treated human plasma and of quarantine fresh frozen plasma. Vox Sang. 1998;74 (Suppl 1):219-223.
43. Guidelines on oral anticoagulation: third edition. Br J Haematol. 1998;101:374-387.
44. Ansell J, Hirsh J, Dalen J, Bussey H, Anderson D, Poller L, Jacobson A, Deykin D, Matchar D. Managing oral anticoagulant therapy. Chest. 2001;119:22S-38S
45. Hanley JP. Warfarin reversal. J Clin Pathol. 2004;57:1132-1139.
46. Bianco C. Choice of human plasma preparations for transfusion. Transfus Med Rev. 1999;13:84-88.
47. Fiore LD, Scola MA, Cantillon CE, Brophy MT. Anaphylactoid reactions to vitamin K. J Thromb Thrombolysis. 2001;11:175-183.
48. Riegert-Johnson DL, Volcheck GW. The incidence of anaphylaxis following intravenous phytonadione (vitamin K1): a 5-year retrospective review. Ann Allergy Asthma Immunol. 2002;89:400-406.
49. Raj G, Kumar R, McKinney WP. Time course of reversal of anticoagulant effect of warfarin by intravenous and subcutaneous phytonadione. Arch Intern Med. 1999;159:2721-2724.
50. Makris M, Greaves M, Phillips WS, Kitchen S, Rosendaal FR, Preston EF. Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost. 1997;77:477-480.
51. Pindur G, Morsdorf S, Schenk JF, Krischek B, Heinrich W, Wenzel E. The overdosed patient and bleedings with oral anticoagulation. Semin Thromb Hemost. 1999;25:85-88.
52. Hellstern P, Muntean W, Schramm W, Seifried E, Solheim BG. Practical guidelines for the clinical use of plasma. Thromb Res. 2002;107 (Suppl 1):S53-S57.
53. O'Shaughnessy DF, Atterbury C, Bolton Maggs P, Murphy M, Thomas D, Yates S, Williamson LM. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol. 2004;126:11-28.
54. Makris M, Watson HG. The management of coumarin-induced over-anticoagulation Annotation. Br J Haematol. 2001;114:271-280.
55. Brody DL, Aiyagari V, Shakleford AM, Diringer MN. Use of recombinannt factor VIIa in patients with warfarin-associated intracranial hemorrhage. Neurocritical Care. 2005;2:263-267.
56. Gilstad CW. Anaphylactic transfusion reactions. Curr Opin Hematol. 2003;10:419-423.
57. Pomper GJ, Wu Y, Snyder EL. Risks of transfusion-transmitted infections: 2003. Curr Opin Hematol. 2003;10:412-418.
58. Hellstern P, Beeck H, Fellhauer A, Fischer A, Faller-Stockl B. Measurement of factor VII and of activated factor VII in healthy individuals and in prothrombin complex concentrates. Thromb Res. 1997;86:493-504.
59. Arun B, Kessler CM. Clinical manifestation and therapy of hemophilias. In: Colman RW, Hirsh J, Marder VJ, Clowes AW, George JN, eds. Hemostasis and thrombosis. London: Lippincott Williams & Wilkins; 2000:815-824.
60. Fredriksson K, Norrving B, Stromblad LG. Emergency reversal of anticoagulation after intracerebral hemorrhage. Stroke. 1992;23:972-977.
61. Sjöblom L, Hardemark HG, Lindgren A, Norrving B, Fahlen M, Samuelsson M, Stigendal L, Stockelberg D, Taghavi A, Wallrup L, Wallvik J. Management and prognostic features of intracerebral hemorrhage during anticoagulant therapy: a Swedish multicenter study. Stroke. 2001;32:2567-2574.
62. McNeill SA, Ewing JC, Wallace WA, Stewart LH. Venous infarction of a testicle following factor IX concentrate (DEFIX). Br J Haematol. 1998;101:210.
63. Roddie PH, Stirling C, Mayne EE, Ludlam CA. Thrombosis and disseminated intravascular coagulation following treatment with the prothrombin complex concentrate, DEFIX. Thromb Haemost. 1999;81:667.
64. Kohler M, Hellstern P, Lechler E, Uberfuhr P, Muller-Berghaus G. Thromboembolic complications associated with the use of prothrombin complex and factor IX concentrates. Thromb Haemost. 1998;80:399-402.
65. Hellstern P. Production and composition of prothrombin complex concentrates: correlation between composition and therapeutic efficiency. Thromb Res. 1999(supp);95:S7-S12.
66. Kohler M, Habauer G, Miyashita C, Braun B, Morsdorf S, Pindur G, Heiden M, Rose S, Ernert P. [Quality control of prothrombin complex preparations: in vivo and in vitro findings]. Beitr Infusionsther. 1990;26:186-189.
67. Boffard KD, Riou B, Warren B, Choong PI, Rizoli S, Rossaint R, Axelsen M, Kluger Y. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma. 2005;59:8-18.
68. Ghorashian S, Hunt BJ. "Off-license" use of recombinant activated factor VII. Blood Rev. 2004;18:245-259.
69. Goodnough LT, Lublin DM, Zhang L, Despotis G, Eby C. Transfusion medicine service policies for recombinant factor VIIa administration. Transfusion. 2004;44:1325-1331.
70. Erhardtsen E, Nony P, Dechavanne M, French P, Boissel JP, Hedner U. The effect of recombinant factor VIIa (NovoSeven) in healthy volunteers receiving acenocoumarol to an International Normalized Ration above 2.0. Blood Coagul Fibrinolysis. 1998;9:741-748.
71. Sorensen B, Johansen P, Nielsen GL, Sorensen JC, Ingerslev J. Reversal of the International Normalized Ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis: clinical and biochemical aspects. Blood Coagul Fibrinolysis. 2003;14:469-477.
72. Baker RI, Coughlin PB, Gallus AS, Harper PL, Salem HH, Wood EM. Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thromb Haemost. Med J Aust. 2004;181:492-497.
73. Phan TG, Koh M, Wijdicks EF. Safety of discontinuation of anticoagulation in patients with intracranial hemorrhage at high thromboembolic risk. Arch Neurol. 2000;57:1710-1713.
74. Ananthasubramaniam K, Beattie JN, Rosman HS, Jayam V, Borzak S. How safely and for how long can warfarin therapy be withheld in prosthetic heart valve patients hospitalized with a major hemorrhage? Chest. 2001;119:478-484.
75. Bertram M, Bonsanto M, Hacke W, Schwab S. Managing the therapeutic dilemma: patients with spontaneous intracerebral hemorrhage and urgent need for anticoagulation. J Neurol. 2000;247:209-214.
76. Hacke W. The dilemma of anticoagulation for patients with intracranial hemorrhage or how wide is the strait between Skylla and Karybdis? Editorial. Neurology. 2000;57:1682-1684.
77. Eckman MH, Rosand J, Knudsen KA, Singer DE, Greenberg SM. Can patients be anticoagulated after intracerebral hemorrhage? A decision analysis. Stroke. 2003;34:1710-1716.
78. Wijdicks EF, Diringer MN. Middle cerebral artery territory infarction and early brain swelling: progression and effect of age on outcome. Mayo Clin Proc. 1998;73:829-836.
79. Leira R, Davalos A, Silva Y, Gil-Peralta A, Tejada J, Garcia M, Castillo J. Early neurologic deterioration in intracerebral hemorrhage: predictors and associated factors. Neurology. 2004;63:461-467.
80. Jackson CM, Esnouf MP, Lindahl TL. A critical evaluation of the prothrombin time for monitoring oral anticoagulant therapy. Pathophysiol Haemost Thromb. 2003;33:43-51.
81. Sorensen B, Johansen P, Christiansen K, Woelke M, Ingerslev J. Whole blood coagulation thrombelastographic profiles employing minimal tissue factor activation. J Thromb Haemost. 2003;1:551-558.